Coya Therapeutics (COYA) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Coya Therapeutics (COYA) over the past year, gaining 61.6% versus a loss of 20.9%. Coya Therapeutics is the larger company by market cap ($117.1 million vs $111.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | RANI |
|---|---|---|
| Share price | $4.99 | $0.792 |
| Market cap | $117.05M | $111.29M |
| 1-day change | +1.63% | -2.48% |
| YTD return | -13.97% | -41.33% |
| 1-year return | -20.92% | +61.63% |
| 5-year return | — | -95.98% |
| EPS (TTM) | $-1.07 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $3.87 |
| 52-week low | $3.71 | $0.445 |
| Distance from 52-week high | -35.61% | -79.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +204.81% | +809.09% |
| Average volume | 158.05K | 743.68K |
| Shares outstanding | 23.46M | 115.42M |
| Employees | 8 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed COYA by 82.6 percentage points over the past year.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Healthcare · Biotechnology · 8 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Healthcare · Biotechnology · 69 employees
COYA vs RANI FAQ
Which is bigger, Coya Therapeutics or Rani Therapeutics?
Coya Therapeutics (COYA) is larger, with a market capitalization of $117.05M compared with $111.29M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, COYA or RANI?
RANI returned +61.63% over the past 12 months, compared with -20.92% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.